AMGN - AMGEN INC

336.29
6.700   1.992%

Share volume: 3,079,158
Last Updated: 05-12-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$329.59
6.70
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
57%
Profitability 73%
Dept financing 43%
Liquidity 27%
Performance 51%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.38%
1 Month
-3.87%
3 Months
-8.91%
6 Months
0.09%
1 Year
24.34%
2 Year
9.03%
Key data
Stock price
$336.29
P/E Ratio 
24.32
DAY RANGE
$329.80 - $338.49
EPS 
$14.48
52 WEEK RANGE
$264.15 - $391.29
52 WEEK CHANGE
$28.22
MARKET CAP 
189.671 B
YIELD 
2.75%
SHARES OUTSTANDING 
539.708 M
DIVIDEND
$2.52
EX-DIVIDEND DATE
05-15-2026
NEXT EARNINGS DATE
08-05-2025
BETA 
0.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,916,543
AVERAGE 30 VOLUME 
$2,653,838
Company detail
CEO: Robert A. Bradway
Region: US
Website: amgen.com
Employees: 25,200
IPO year: 1984
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Recent news